DCVC

DCVC, originally Data Collective, is a deep tech venture firm that has emerged as one of the more credible AI-native investors in healthcare and life sciences. With approximately $4 billion in assets under management, thirteen funds raised to date, and a team of around forty-five professionals, DCVC backs entrepreneurs using computational approaches to solve large, slow-moving problems across climate, defense, space, manufacturing, and human health. The firm’s healthcare and life sciences practice is institutionalized as DCVC Bio, a sister franchise launched in 2018 to invest specifically in AI-enabled drug discovery, computational biology, and engineered biomanufacturing. DCVC Bio recently closed its third fund at an oversubscribed $400 million, bringing the bio franchise’s cumulative capital to roughly $1 billion.

Managing partners Matt Ocko and Zachary Bogue lead the broader DCVC platform from offices in Palo Alto and San Francisco. DCVC Bio is run by managing partners Dr. Kiersten Stead, a molecular biologist with a PhD in genetics, and Dr. John Hamer, a veteran agricultural and biotech operator. The bio team applies a deep operating understanding of genetics, chemistry, molecular biology, industrial fermentation, and AI to companies that sit at the boundary between computation and wet lab. Headline portfolio companies include Recursion Pharmaceuticals, the AI-driven phenotypic drug discovery company that went public in 2021 and runs its BioHive supercomputer on Nvidia GPUs to train models on its own lab data; Relation Therapeutics, which combines single-cell genomics with AI to identify drug targets; Unlearn, the digital-twin platform that ran a landmark Alzheimer’s trial collaboration with Johnson & Johnson showing 33 percent control-arm reduction without statistical loss; and a deep bench across cell therapy manufacturing, structural biology, and synthetic biology.

Check sizes range from $5 million at seed and early Series A up to $30 million plus at Series B and C, with DCVC almost always taking a lead or co-lead position and a board seat. The firm reserves substantial follow-on capital and has the capacity to support companies through long bio timelines. Geographic scope is global with a US and UK center of gravity, and DCVC Bio has been particularly active in cross-Atlantic deals where AI-led founders sit in academic clusters in Boston, Cambridge, London, and Toronto.

Founders who should approach DCVC are scientific or technical founders building computationally native businesses with a defensible data moat, ideally with PhD-level domain expertise and a thesis about why AI changes the unit economics of drug discovery, diagnostic development, or biomanufacturing. The bar is high. DCVC pattern-matches against companies that look like the next Recursion or Unlearn, meaning founders should have either a technical breakthrough, a proprietary biology asset, or an unusual data-acquisition strategy. Founders pitching shallow ML wrappers, generic LLM-for-doctors apps, or healthcare services without a deep tech wedge should not waste cycles here. Therapeutics-only founders without a computational thesis should pitch Third Rock, Versant, or Vivo instead.

Entry path is best run through portfolio CEOs, academic advisors, and the firm’s DCVC Bio team directly. Stead and Hamer are publicly accessible at conferences including JPMorgan Healthcare, BIO, and the deep tech circuits, and the broader DCVC partnership runs an active editorial presence on its website. Cold inbound through the website does get triaged but converts at low rates without a strong technical or scientific signal. Diligence is rigorous and frequently includes independent technical review by DCVC’s network of operating advisors, which can extend the process to six or eight weeks for novel platforms.

The pitch should lead with the computational thesis, the data, and the asset or product roadmap. Skip the slide on TAM and skip the slide on the AI hype cycle. DCVC partners want to see why your model architecture, your wet lab loop, or your manufacturing approach yields a step function rather than an incremental gain, and they want a founder who can defend the science under pressure. They also want a clear plan to translate computational advantage into an asset, an FDA or regulatory milestone, or a revenue-generating platform within a defensible time horizon. Founders who can articulate the bridge between code and clinic, with conviction and quantitative evidence, will find DCVC one of the most useful and intellectually rigorous partners in the healthcare AI category.